Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Wins US Approval for Antibiotic Fetroja
The US FDA has approved Shionogi’s novel antibiotic cefiderocol, which now carries the brand name of Fetroja, for the treatment of complicated urinary tract infections (cUTI) in patients aged 18 and older who have limited or no alternative options. The…
To read the full story
Related Article
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Shionogi’s Novel Antibiotic Cefiderocol Approved in Europe
April 30, 2020
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Shionogi’s Antibiotic Fetroja Now Available in US
February 26, 2020
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
- Novel Antibiotic Cefiderocol Accepted for EMA Review: Shionogi
April 2, 2019
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…